Administration Officials: Lack Of March-In Protections Won’t Spur Price Gouging

Trump administration officials told a Senate Appropriations panel that reported moves by several COVID-19 vaccine and drug developers to eliminate “march-in” language from their contracts with HHS should not lead to price gouging. Committee Democrats on Thursday (July 2) repeatedly questioned NIH Director Francis Collins and HHS Biomedical Advanced Research and Development Authority Acting Director Gary Disbrow about the matter. The federal government has never used its march-in rights, which allow the government to override patents and grant licenses for...